3-methyl-1H-1,2-benzodiazepine | 84201-99-0

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: 3-methyl-1H-1,2-benzodiazepine
• 英文别名: benzodiazepine carbon；3-methyl-2H-1,2-benzodiazepine
• CAS: 84201-99-0
• 化学式: C₁₀H₁₀N₂
• 分子量: 158.203
• InChiKey: RNCQBHLAWVJNDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-1H-1,2-benzodiazepine 、 氯甲酸乙酯 以52%的产率得到
  参考文献：
  名称：

  KURITA, JYOJI;ENKAKU, MICHIKO;TSUCHIYA, TAKASHI, CHEM. AND PHARM. BULL., 1983, 31, N 10, 3684-3690

  摘要：

  DOI：
• 作为产物：
  描述：

  2,4,6-Trimethyl-benzenesulfonate1-amino-2-methyl-quinolinium; 以60%的产率得到
  参考文献：
  名称：

  KURITA, JYOJI;ENKAKU, MICHIKO;TSUCHIYA, TAKASHI, CHEM. AND PHARM. BULL., 1983, 31, N 10, 3684-3690

  摘要：

  DOI：

文献信息

• Lactams substituted by cyclic succinates as inhibitors of a beta protein production
  申请人：——

  公开号：US20020137737A1

  公开（公告）日：2002-09-26

  This invention relates to novel lactams having the Formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  这项发明涉及具有式(I)的新型内内酰胺，以及它们的药物组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ-肽的产生，从而防止淀粉样蛋白的神经沉积形成。更具体地说，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，如阿尔茨海默病和唐氏综合征。
• Studies on diazepines. XX. Acylations of 1H-1,2-thienodiazepines and 1H-1,2-benzodiazepines.
  作者：JYOJI KURITA、MICHIKO ENKAKU、TAKASHI TSUCHIYA

  DOI：10.1248/cpb.31.3684

  日期：——

  Treatment of the N-unsubstituted 3-methyl-1H-1, 2-thieno[2, 3-c]diazepine (3) with ethyl chloroformate, acetyl chloride, or benzoyl chloride in benzene resulted in ring-conversion to give the corresponding 3-acyl-3H-1, 3-thieno[2, 3-d]diazepines (4), whereas similar treatment of the N-substituted thieno[2, 3-c]diazepine (6) gave the exo-methylene compound (7) and treatment of the fully unsubstituted thieno[2, 3-c]diazepine (8) gave the thieno[2, 3-b]pyridine derivatives (9) and (10). On the other hand, the N-unsubstituted 3-methyl-1H-1, 2-benzo[c]diazepines (16), upon treatment with ethyl chloroformate in benzene, gave the exo-methylene compounds (17), and in the case of the diazepines (16b, c) having an electron-donating group in the 7-position, the 3-acyl-3H-1, 3-benzo[d]diazepines (19) were also formed. The mechanisms of these acylations are discussed.

  在苯中用氯甲酸乙酯、乙酰氯或苯甲酰氯处理 N-未取代的 3-甲基-1H-1, 2-噻吩并[2, 3-c]二氮杂卓 (3) 会发生环转化，得到相应的 3-酰基-3H-1, 3-噻吩并[2, 3-d]二氮杂卓 (4)、而对 N-取代的噻吩并[2，3-c]二氮杂卓（6）进行类似处理，可得到外亚甲基化合物（7）；对完全未取代的噻吩并[2，3-c]二氮杂卓（8）进行处理，可得到噻吩并[2，3-b]吡啶衍生物（9）和（10）。另一方面，N-未取代的 3-甲基-1H-1, 2-苯并[c]二氮杂卓（16）在苯中经氯甲酸乙酯处理后，生成外亚甲基化合物（17），而在 7 位上有一个电子供能基团的二氮杂卓（16b、c）还生成了 3-酰基-3H-1, 3-苯并[d]二氮杂卓（19）。本文讨论了这些酰化反应的机理。
• Acylations of 1H-1,2-thieno-and 1H-1,2-benzo-diazepines: ring-conversion into 1,3-diazepines
  作者：Jyoji Kurita、Michiko Enkaku、Takashi Tsuchiya

  DOI：10.1039/c39820000990

  日期：——

  the 1H-1,2-benzodiazepines (7) having an electron-donating substituent in the 7-position with ethyl chloroformate, acetyl chloride, or benzoyl chloride in benzene results in ring-conversion to give the corresponding 1,3-diazepines (3) and (12).

  用苯甲酸氯甲酸酯，乙酰氯或苯甲酰氯处理在7位具有给电子取代基的1 H -1,2-噻吩二氮杂（1）和1 H -1,2-苯并二氮杂（7）导致环转化，得到相应的1，3-二氮杂（（3）和（12）。
• Lactams substituted by cyclic succinates as inhibitors of Abeta protein production
  申请人：Olson E. Richard

  公开号：US20050261274A1

  公开（公告）日：2005-11-24

  This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式（I）的新型内酰胺，其制药组成物和使用方法。这些新化合物抑制淀粉样前体蛋白的处理，更具体地抑制Aβ-肽的产生，从而防止神经元中淀粉样蛋白的沉积形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，如阿尔茨海默病和唐氏综合症。
• Lactams substituted by cyclic succinates as inhibitors of A-beta protein production
  申请人：——

  公开号：US20030119815A1

  公开（公告）日：2003-06-26

  This invention relates to novel lactams having the Formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式(I)的新型内酰胺，以及它们的制药组合物和使用方法。这些新化合物抑制淀粉样前体蛋白的处理，更具体地抑制Aβ-肽的产生，从而防止神经元中出现淀粉样蛋白质的沉积。更具体地说，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，如阿尔茨海默病和唐氏综合症。